A lactylation-ferroptosis cross-talk gene signature predicts hepatocellular carcinoma prognosis and reveals STMN1/PRDX1 as therapeutic targets.

ABSTRACT:

Introduction

Hepatocellular carcinoma (HCC) presents great difficulties for diagnosis and prognosis. Metabolic reprogramming and ferroptosis resistance play critical roles in HCC development and progression.

Methods

We combined transcriptome data from TCGA-LIHC to screen out lactylation-ferroptosis-related genes (LFRGs). Based on LASSO-Cox regression and multivariate analysis, a 4-gene-prognostic signature (STMN1, PRDX1, TP53, G6PD) was constructed.

Results

The signature stratified HCC patients into two risk subgroups with obvious survival differences (P < 0.001). Functional validation demonstrated that STMN1/PRDX1 knockdown in MHCC-97H/SNU-449 cells could decrease the expression of LDHA (lactylation enzyme) and GPX4 (ferroptosis inhibitor), and further inhibited cell

SUBMITTER: Meng J 

PROVIDER: S-EPMC12702848 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature